The common severe Z mutation (E342K) of α1-antitrypsin forms intracellular polymers that are associated with liver cirrhosis. The native fold of this protein is well-established and models have been proposed from crystallographic and biophysical data for the stable inter-molecular configuration that terminates the polymerization pathway. Despite these molecular ‘snapshots’, the details of the transition between monomer and polymer remain only partially understood. We surveyed the RCL (reactive centre loop) of α1-antitrypsin to identify sites important for progression, through intermediate states, to polymer. Mutations at P14P12 and P4, but not P10P8 or P2P1′, resulted in a decrease in detectable polymer in a cell model that recapitulates th...
α1-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary ...
Serpins are important regulators of proteolytic pathways with an antiprotease activity that involves...
AbstractThe wild-type form of plasminogen activator inhibitor type-2 (PAI-2) and the pathogenic Z-mu...
The common severe Z mutation (E342K) of α1-antitrypsin forms intracellular polymers that are associa...
The common severe Z mutation (E342K) of alpha(1)-antitrypsin forms intracellular polymers that are a...
The common severe Z mutation (E342K) of α1-antitrypsin forms intracellular polymers that are associa...
Protease inhibitors of the serpin family are characterised by a metastable native fold which is nece...
The common Z mutant (Glu342Lys) of α1-antitrypsin results in the formation of polymers that are reta...
AbstractThe human serine protease inhibitor (serpin) α-1 antitrypsin (α1-AT) protects tissues from p...
AbstractThe common Z mutant (Glu342Lys) of α1-antitrypsin results in the formation of polymers that ...
The serpinopathies are among a diverse set of conformational diseases that involve the aberrant self...
The formation of ordered Z (Glu342Lys) α1‐antitrypsin polymers in hepatocytes is central to liver di...
AbstractAlpha1-antitrypsin deficiency results from point mutations that distort the structure of the...
A monoclonal antibody (mAb) that binds to a transient intermediate may act as a catalyst for the cor...
The serpinopathies result from the ordered polymerization of mutants of members of the serine protei...
α1-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary ...
Serpins are important regulators of proteolytic pathways with an antiprotease activity that involves...
AbstractThe wild-type form of plasminogen activator inhibitor type-2 (PAI-2) and the pathogenic Z-mu...
The common severe Z mutation (E342K) of α1-antitrypsin forms intracellular polymers that are associa...
The common severe Z mutation (E342K) of alpha(1)-antitrypsin forms intracellular polymers that are a...
The common severe Z mutation (E342K) of α1-antitrypsin forms intracellular polymers that are associa...
Protease inhibitors of the serpin family are characterised by a metastable native fold which is nece...
The common Z mutant (Glu342Lys) of α1-antitrypsin results in the formation of polymers that are reta...
AbstractThe human serine protease inhibitor (serpin) α-1 antitrypsin (α1-AT) protects tissues from p...
AbstractThe common Z mutant (Glu342Lys) of α1-antitrypsin results in the formation of polymers that ...
The serpinopathies are among a diverse set of conformational diseases that involve the aberrant self...
The formation of ordered Z (Glu342Lys) α1‐antitrypsin polymers in hepatocytes is central to liver di...
AbstractAlpha1-antitrypsin deficiency results from point mutations that distort the structure of the...
A monoclonal antibody (mAb) that binds to a transient intermediate may act as a catalyst for the cor...
The serpinopathies result from the ordered polymerization of mutants of members of the serine protei...
α1-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary ...
Serpins are important regulators of proteolytic pathways with an antiprotease activity that involves...
AbstractThe wild-type form of plasminogen activator inhibitor type-2 (PAI-2) and the pathogenic Z-mu...